HeartBeam Inc. will attend the JP Morgan 2026 Annual Healthcare Conference in San Francisco from January 12-15, 2026, where company executives will meet with investors and potential partners to discuss recently obtained regulatory clearances and upcoming commercialization plans. Chief Executive Officer Robert Eno and Chief Financial Officer Timothy Cruickshank will be available for off-site meetings during the conference to discuss the company's patented technology and market strategy. The company's participation in this prominent healthcare investment conference comes shortly after receiving 510(k) clearance from the U.S. Food and Drug Administration for its cable-free 12-lead electrocardiogram synthesis software for arrhythmia assessment.
This regulatory milestone precedes a planned limited U.S. commercial launch scheduled for the first quarter of 2026. The technology represents a significant advancement in cardiac monitoring, enabling the collection of ECG signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG format. HeartBeam's platform technology is designed for portable devices that can be used outside traditional medical facilities, potentially transforming how cardiac conditions are detected and monitored. The system records, stores, and transfers a patient's 3-lead ECG acquired from five electrodes, with the synthesis software creating a visual 12-lead ECG representation for manual assessment of specific non-life-threatening arrhythmias.
According to company information available at https://HeartBeam.com, the technology has received multiple FDA clearances, including for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology, which is intended for adult patients in both clinical and home settings. The synthesized 12-lead ECG output is specifically cleared for assessment of normal sinus rhythm and several non-life-threatening arrhythmias, including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex.
The technology is not intended to replace standard 12-lead ECGs or for assessment of more serious cardiac conditions. HeartBeam's presence at the JP Morgan conference signals the company's transition from development to commercialization phase, with discussions expected to focus on partnership opportunities and market expansion strategies. The technology's potential to deliver actionable cardiac intelligence outside medical facilities could address growing needs in remote patient monitoring and telehealth services. Additional information about the company is available through its newsroom at https://ibn.fm/BEAT, though investors should review relevant disclaimers and risk factors associated with forward-looking statements.
